Company: CMND
Filing Date: 2025-09-19
Form Type: F-1
Source: 0001213900-25-089545
Chunk: 45

Company: Clearmind Medicine Inc.
Filing Date: 2025-09-19
Form: F-1
Chunk 45
---
 indemnification of our directors and executive officers
for expenses, judgments, fines and settlement amounts incurred by such persons in any action or proceeding arising out of this person’s
services as a director or executive officer or at our request. We believe that these provisions in our articles of association and indemnification
agreements are necessary to attract and retain qualified persons as directors and executive officers.

The above description of the
limitation of liability and indemnification provisions of our articles of association of incorporation, our articles of association and
our indemnification agreements is not complete and is qualified in its entirety by reference to these documents, each of which will be
filed as an exhibit to this registration statement to which this prospectus forms a part.

The limitation of liability
and indemnification provisions in our articles of association may discourage shareholders from bringing a lawsuit against our directors
for breach of their fiduciary duties. They may also reduce the likelihood of derivative litigation against directors and officers, even
though an action, if successful, might benefit us and our shareholders. A shareholder’s investment may be harmed to the extent we
pay the costs of settlement and damage awards against directors and officers pursuant to these indemnification provisions.

We maintain a general liability
insurance policy that covers certain liabilities of directors and officers of our corporation arising out of claims based on acts or omissions
in their capacities as directors or officers.

In any placement agent agreement
we enter into in connection with the sale of common shares being registered hereby, the placement agent will agree to indemnify, under
certain conditions, us, our directors, our officers and persons who control us within the meaning of the Securities Act, against certain
liabilities.

Item 7. Recent Sales of Unregistered Securities.

Set
forth below are the sales of all unregistered securities of ours sold by us within the past three years (i.e., since January 1, 2022,
up to the date of this registration statement) which were not registered under the Securities Act. We believe that each of such issuances
was exempt from registration under the Securities Act in reliance on Section 4(a)(2) of the Securities Act, Rule 701 and/or Regulation
S under the Securities Act.

On February 8, 2022, we entered
into a private placement agreement with Xylo Technologies Ltd. (formerly Medigus), or Xylo, pursuant to which we will raise approximately
CAD$1.6 million (approximately $1.25 million). As consideration for the